IS2268B - Gúanín afleiður - Google Patents

Gúanín afleiður

Info

Publication number
IS2268B
IS2268B IS4527A IS4527A IS2268B IS 2268 B IS2268 B IS 2268B IS 4527 A IS4527 A IS 4527A IS 4527 A IS4527 A IS 4527A IS 2268 B IS2268 B IS 2268B
Authority
IS
Iceland
Prior art keywords
guanine derivatives
guanine
derivatives
Prior art date
Application number
IS4527A
Other languages
English (en)
Icelandic (is)
Other versions
IS4527A (is
Inventor
Howard Carter Barry
Muse Partin Jane
Gregory Varlashkin Peter
Augustus Winnike Richard
Triangle Park Research
Bayne Grubb William Iii
Alan Conway Gregory
George Lake Philip
Michael Skinner David
James Whatrup David
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2268(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of IS4527A publication Critical patent/IS4527A/is
Publication of IS2268B publication Critical patent/IS2268B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IS4527A 1995-01-20 1997-07-15 Gúanín afleiður IS2268B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (2)

Publication Number Publication Date
IS4527A IS4527A (is) 1997-07-15
IS2268B true IS2268B (is) 2007-07-15

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4527A IS2268B (is) 1995-01-20 1997-07-15 Gúanín afleiður

Country Status (40)

Country Link
US (1) US6107302A (OSRAM)
EP (1) EP0804436B1 (OSRAM)
JP (1) JP3176633B2 (OSRAM)
KR (1) KR100376074B1 (OSRAM)
CN (1) CN1049893C (OSRAM)
AP (1) AP662A (OSRAM)
AR (1) AR002270A1 (OSRAM)
AT (1) ATE302777T1 (OSRAM)
AU (1) AU702794B2 (OSRAM)
BG (1) BG63393B1 (OSRAM)
BR (1) BR9606768A (OSRAM)
CA (1) CA2210799C (OSRAM)
CY (1) CY2531B1 (OSRAM)
CZ (1) CZ297065B6 (OSRAM)
DE (1) DE69635106T2 (OSRAM)
DK (1) DK0804436T3 (OSRAM)
EA (1) EA000364B1 (OSRAM)
EE (1) EE03528B1 (OSRAM)
ES (1) ES2248806T3 (OSRAM)
FI (1) FI973063A7 (OSRAM)
GB (1) GB9501178D0 (OSRAM)
GE (1) GEP20001940B (OSRAM)
HR (1) HRP960024B1 (OSRAM)
HU (1) HU222993B1 (OSRAM)
IL (1) IL116831A (OSRAM)
IN (1) IN182468B (OSRAM)
IS (1) IS2268B (OSRAM)
NO (1) NO315558B1 (OSRAM)
NZ (1) NZ298851A (OSRAM)
OA (1) OA10499A (OSRAM)
PL (1) PL182175B1 (OSRAM)
RO (1) RO118693B1 (OSRAM)
RS (1) RS49518B (OSRAM)
SI (1) SI0804436T1 (OSRAM)
SK (1) SK285329B6 (OSRAM)
TR (1) TR199700656T1 (OSRAM)
UA (1) UA46001C2 (OSRAM)
UY (1) UY25779A1 (OSRAM)
WO (1) WO1996022291A1 (OSRAM)
ZA (1) ZA96449B (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
KR20000070223A (ko) * 1997-01-17 2000-11-25 에가시라 구니오 신규한 ｚ-발라사이클로비르 결정
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
HU230382B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
PL374179A1 (en) * 2001-09-07 2005-10-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
JP2005508993A (ja) * 2001-11-14 2005-04-07 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビルの合成及び精製
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
ES2270172T3 (es) * 2002-10-16 2007-04-01 Teva Pharmaceutical Industries Ltd. Procedimiento para reducir alcoholes residuales en hidrocloruro de valaciclovir cristalino.
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
MXPA06008197A (es) * 2004-01-21 2007-04-02 Teva Pharma Proceso para la preparacion de clorhidrato de valaciclovir.
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006011874A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries, Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
WO2007128721A1 (de) 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphe
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
BR112012032579B1 (pt) 2010-06-24 2021-05-11 Boehringer Ingelheim International Gmbh uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ATE199719T1 (de) * 1993-06-10 2001-03-15 Rolabo Sl Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
DK0804436T3 (da) 2005-12-27
NO315558B1 (no) 2003-09-22
AU702794B2 (en) 1999-03-04
RO118693B1 (ro) 2003-09-30
GB9501178D0 (en) 1995-03-08
EP0804436B1 (en) 2005-08-24
HRP960024B1 (en) 2005-08-31
EE03528B1 (et) 2001-10-15
ATE302777T1 (de) 2005-09-15
US6107302A (en) 2000-08-22
JPH11503718A (ja) 1999-03-30
AU4453996A (en) 1996-08-07
AR002270A1 (es) 1998-03-11
TR199700656T1 (xx) 1998-03-21
DE69635106D1 (de) 2005-09-29
GEP20001940B (en) 2000-02-05
SI0804436T1 (sl) 2006-02-28
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
KR100376074B1 (ko) 2003-06-02
CZ229497A3 (en) 1997-12-17
BR9606768A (pt) 1997-12-30
EA000364B1 (ru) 1999-06-24
KR19980701525A (ko) 1998-05-15
CY2531B1 (en) 2006-04-12
SK285329B6 (sk) 2006-11-03
EP0804436A1 (en) 1997-11-05
RS49518B (sr) 2006-10-27
AP662A (en) 1998-08-19
SK96597A3 (en) 1998-02-04
HRP960024A2 (en) 1997-10-31
IL116831A (en) 1998-10-30
ES2248806T3 (es) 2006-03-16
CA2210799C (en) 2008-06-10
FI973063A0 (fi) 1997-07-18
FI973063L (fi) 1997-09-18
IL116831A0 (en) 1996-05-14
NZ298851A (en) 1999-01-28
EE9700175A (et) 1998-02-16
ZA96449B (en) 1996-08-07
HUP9801836A2 (hu) 1999-05-28
CA2210799A1 (en) 1996-07-25
NO973326D0 (no) 1997-07-18
IN182468B (OSRAM) 1999-04-17
IS4527A (is) 1997-07-15
FI973063A7 (fi) 1997-09-18
CZ297065B6 (cs) 2006-08-16
UY25779A1 (es) 2000-08-21
WO1996022291A1 (en) 1996-07-25
AP9701058A0 (en) 1997-10-31
MX9705462A (es) 1997-10-31
YU3396A (sh) 1998-12-23
CN1179159A (zh) 1998-04-15
JP3176633B2 (ja) 2001-06-18
DE69635106T2 (de) 2006-06-08
PL321326A1 (en) 1997-12-08
UA46001C2 (uk) 2002-05-15
EA199700124A1 (ru) 1997-12-30
OA10499A (en) 2002-04-10
HUP9801836A3 (en) 1999-06-28
HU222993B1 (hu) 2004-01-28
NO973326L (no) 1997-09-16
BG101833A (bg) 1998-04-30
PL182175B1 (pl) 2001-11-30

Similar Documents

Publication Publication Date Title
IS2268B (is) Gúanín afleiður
DE69611361D1 (de) Chinazolin-derivate
DE69522717D1 (de) Chinazolinderivate
NO974103L (no) Arylsulfonylaminohydroksamsyre-derivater
DE69610698D1 (de) Chinazolin-derivate
PT833828E (pt) Derivados de rapamicina
BR9611834A (pt) Derivados de oximetóxi-3-aril-pirona
ATE199150T1 (de) Diphenylmethylenpiperidin-derivate
NO964667D0 (no) Purin-6-on-derivater
DE69601527D1 (de) Pyrrolylbenzimidazol-Derivate
ATA100695A (de) Prothrombin-derivate
PT856007E (pt) Derivados de ciclopeptidos
DE69627830D1 (de) Pyrazol-derivate
DE69628200D1 (de) Diarylalkenylamin-derivate
NO961404D0 (no) 4-indolylpiperazinyl-derivater
ATE202093T1 (de) 4-amino-benzoylguanidin-derivate
DE59610106D1 (de) Fluorbenzylether-Derivate
ATE177102T1 (de) Chromanderivate
ATE225347T1 (de) Aza-anthracyclinone-derivate
BR9603508A (pt) Derivados de alquenil-benzoilguanidina
ATE202088T1 (de) 4-mercapto-benzoylguanidin-derivate
DE69620514D1 (de) 5-aminoflavon-derivate
ATA45796A (de) Lysin-prolin-derivate
BR9603733A (pt) Derivados de cloropiridilcarbonila
DK0705833T3 (da) DC-89-derivat